Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563666 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL14811134 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL15955034 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL5254866 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL15612596 | 0.77 | S1PR3 (0.34) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL681840 | 0.76 | GBA1 (0.41) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL7263792 | 0.74 | S1PR3 (0.40) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL31473349 | 0.74 | S1PR3 (0.35) | KDM4EALDH1A1S1PR3S1PR4S1PR2 | |
| SCHEMBL20525062 | 0.74 | GBA1 (0.33) | KDM4EALDH1A1S1PR3S1PR4ADRA2A | |
| SCHEMBL20361485 | 0.74 | GBA1 (0.37) | KDM4EALDH1A1S1PR3S1PR4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12509439-B2 | Anti-malarial agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-101163678-A | Pyridylmethylsulfone derivative | DAIICHI SANKYO CO LTD (JP) | 2008-04-16 | — | — | CN | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1867636-A1 | PYRIDYLMETHYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | CORTEVA AGRISCIENCE LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | CORTEVA AGRISCIENCE LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | CORTEVA AGRISCIENCE LLC | 2007-08-30 | — | — | US | disclosed |
| WO-2007095229-A2 | INSECTICIDAL N-SUBSTITUTED (6-HALOALKYLPYRIDIN-3-YL)ALKYL SULFOXIMINES | DOW AGROSCIENCES LLC (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095229-A2 | INSECTICIDAL N-SUBSTITUTED (6-HALOALKYLPYRIDIN-3-YL)ALKYL SULFOXIMINES | DOW AGROSCIENCES LLC (US) | 2007-08-23 | — | — | WO | disclosed |
| CN-1835950-A | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2006-09-20 | — | — | CN | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, CBR1, CNR1 | KDM4E 1046/4885ALDH1A1 618/4885S1PR3 908/4885 |
| US-12509439-B2 | Anti-malarial agents | RCC1, PFN1, NHERF1 | KDM4E 3704/4885ALDH1A1 1353/4885S1PR3 1448/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | KDM4E 2965/4885ALDH1A1 2200/4885S1PR3 135/4885 |
| US-20070203191-A1 | Insecticidal N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines | NPEPPS, PRDX6, HDHD5 | KDM4E 1486/4885ALDH1A1 2432/4885S1PR3 567/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | KDM4E 1200/4885ALDH1A1 2353/4885S1PR3 1577/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | KDM4E 4822/4885ALDH1A1 100/4885S1PR3 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.